Heterocyclic compounds

A method for treating an interleukin-12 overproduction-related disorder, selected from the group consisting of rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, and insulin-dependent diabetes mellitus, comprising administering to a subject in need thereof an effective amount of the compound of formula (I):

• wherein
• R1 is aryl or heteroaryl;
• each of R2 and R4, independently, is H, halogen, CN, alkyl, ORa, or NRaRb;
• R3 is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORa, OC(O)Ra, OC(O)NRaRb, NRaRb, NRaC(O) Rb, NRaS(O)Rb, NRaS(O)2Rb, NRaC(O)NRbRc, NRaC(S)NRbRc, NRaC(NRb)NRcRd, NRaC(O)ORb, S(O)NRaRb, S(O)2NRaRb, S(O)Ra, S(O)2Ra, C(O)Ra, C(O)ORa, or C(O)NRaRb;
• R5 is H or alkyl;
• n is 0, 1, 2, 3, 4, 5, or 6;
• A is NRe;
• B is CRf;
• X is O, S, S(O), S(O)2, NRe, or C(O);
• Y is a covalent bond, C(O), C═NRa, O, S, S(O), S(O)2, or NRe;
• Z is N or CH;
• each of U and V, independently, is CR;
• and
• W is O, S, or NRe;
• in which each of Ra, Rb, Rc, and Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl;
• Re is H, alkyl, aryl, acyl, or sulfonyl;
• and Rf is H, alkyl, aryl, acyl, sulfonyl, alkoxyl, amino, ester, amide, CN, or halogen.